Expression and clinical significance of LIMD2 in endometrial cancer tissues

XIA Chaohui; WU Rongyi; CHEN Yueyue

doi:10.3969/j.issn.1009-0460.2019.07.010

Abstract：Objective To investigate the expression and clinical significance of LIM domain containing 2 protein (LIMD2) in endometrial cancer tissues. Methods Eighty?nine cases of endometrial cancer tissues, 57 cases of normal endometrial tissues and 61 cases of atypical hyperplasia tissues were collected from January 2014 to December 2017. The expression of LIMD2 in the above tissues was detected by real?time quantitative PCR (QPCR). The efficacy of tissue LIMD2 level for the diagnosis of endometrial cancer was e?valuated by receiver operating characteristic(ROC) curve. The relationship between LIMD2 expression and clinicopathological parame?ters of endometrial cancer ( age, lymph node metastasis, FIGO stage, pathological type, histological grade and myometrial invasion depth) was analyzed. Results The level of LIMD2 in endometrial cancer tissues was 3. 095±1. 236, higher than 1. 297±0. 420 of a?typical hyperplasia tissues and 1. 176±0. 444 of normal endometrial tissues (P＜0. 05). There was no significant difference in the level of LIMD2 between normal endometrium group and atypical hyperplasia group ( P＞0. 05). ROC curve showed that the area under the curve of tissue LIMD2 level for diagnosis of endometrial cancer was 0. 901 (95% CI: 0. 851?0. 951). When 1. 918 was chosen as the cut?off point, the Yoden index was the largest (0. 7865) with the sensitivity of 78. 65% and specificity of 100. 0%. The expression of LIMD2 was not correlated with age and pathological types (P＞0. 05), but with lymph node metastasis, FIGO stage, depth of muscle invasion and histological grade (P＜0. 05). The results of Kaplan?Meier Plotter online database analysis showed that LIMD2 expression was associated with relapse?free survival (HR＝0. 53, 95% CI: 0. 29?0. 98,P＜0. 05), while it was not associated with overall survival (P＞0. 05). Conclusion LIMD2 expression is enhanced and related to lymph node metastasis, FIGO staging, histological grade, depth of muscle invasion and recurrence of endometrial cancer. It may be involved in the occurrence and development of endometrial cancer and may become a new molecular marker for the diagnosis and prediction of endometrial cancer.